Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oraxol + Pembrolizumab in Advanced Solid Tumors
NCT03588039Phase 1Terminated
- Sponsor
- Athenex
- Start
- Oct 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paclitaxel + encequidar in solid tumor, non-small cell lung cancer (NSCLC), gastric cancer (GC) and 1 more (8 arms), sponsored by Athenex. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Tumor Response Rate at 24 months. Started Oct 2018; status: terminated.
02
Drugs
paclitaxel + encequidar
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03588039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588039.